Search - tctmd.com

Displaying 121 - 140 of 273

Sort: Relevancy | Date

Presentation TCT 2016

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Presenter: Sunil V. Rao, Harvey D. White, Salvatore Brugaletta

October 31, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Presenter: Raj Makkar, Lars Sondergaard, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Presenter: Raj Makkar, Lars Sondergaard, Axel Linke

October 31, 2016

Presentation TCT 2016

ABSORB III Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Ron Waksman

October 31, 2016

Presentation TCT 2016

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Presenter: Owen Faris, Mitchell W. Krucoff, Michael R Minogue

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

Introductory Lecture: Defining CHIP/Complex PCI in 2016 - Where We Are and Where We Need to Go

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses

October 31, 2016

Presentation TCT 2016

Keynote Lecture III. National Evaluation System for Health Technology (NEST): Objectives, Accomplishments and Future Directions

Presenter: Owen Faris, Mitchell W. Krucoff, Gregory Daniel

October 31, 2016

Presentation TCT 2016

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Presenter: Owen Faris, Mitchell W. Krucoff, David R. Holmes Jr.

October 31, 2016

Presentation TCT 2016

Device Performance in Pre-Approval Studies vs Unrestricted Real-World Use: Lessons Learned and Future Opportunities

Presenter: Owen Faris, Mitchell W. Krucoff

October 31, 2016

Presentation TCT 2016

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Alan G. Fraser

October 31, 2016

Presentation TCT 2016

Key Note Lecture I. FDA/CDRH State of the Union

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren

October 31, 2016

Presentation TCT 2016

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Presenter: Matthew G. Hillebrenner, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Severe Asymptomatic AS

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Severe AS With Simple and Complex CAD

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Alan Zajarias

October 31, 2016

Presentation TCT 2016

Severe AS With Simple and Complex CAD

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, David Hildick-Smith

October 31, 2016

Presentation TCT 2016

Severe AS and Hypertrophic Cardiomyopathy

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Paul Sorajja

October 31, 2016

Advertisement

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

ABSORB III Critique: Pros and Cons

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Introductory Lecture: Defining CHIP/Complex PCI in 2016 - Where We Are and Where We Need to Go

Keynote Lecture III. National Evaluation System for Health Technology (NEST): Objectives, Accomplishments and Future Directions

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Device Performance in Pre-Approval Studies vs Unrestricted Real-World Use: Lessons Learned and Future Opportunities

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Key Note Lecture I. FDA/CDRH State of the Union

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Severe Asymptomatic AS

Severe AS With Simple and Complex CAD

Severe AS With Simple and Complex CAD

Severe AS and Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content